Skip to main content
. Author manuscript; available in PMC: 2010 May 6.
Published in final edited form as: J Immunol. 2008 Sep 1;181(5):2961–2972. doi: 10.4049/jimmunol.181.5.2961

FIGURE 2.

FIGURE 2

Effects of weekly injection of anti-CD79 mAb on peripheral blood B cells. MRL/lpr-Thy1.1 mice were given weekly i.p. injections of either PBS, control hamster IgG Abs (Hamster IgG), or 0.5 mg each of anti-CD79α and Anti-CD79β (AB) for 17 wk (Table II, Expt. I). Shown are means and SEM of the percentages of peripheral blood lymphocytes that were (A) B220+CD19+ cells; (B) B220+ cells with surface-bound hamster Ab (B220+hIgG+), as detected by anti-hamster Ab; and (C) B220+ cells that bound ex vivo added FITC-anti-CD79β (B220+CD79b+). PBS (n = 3–5 mice); hamster IgG group (n = 3–6); AB (n = 6–8). Numbers of mice were less at later time points either because mice were deceased or sacrificed to examine kidney histology. Except for week 0, the differences between AB and control groups were significant at p < 0.00001 for each time point.